Wednesday, February 20, 2013
Life Technologies dips 8%
Life Technologies dropped 8 percent yesterday to $58.83 on news that potential buyout offers have disappeared because of the recent run up in the firm's market value. On Jan 18, Life Technologies released a press announcement confirming that the bank has hired bankers to conduct a "strategical review" of the company, fueling speculation that private equity firms and larger life sciences companies are looking to buy out the firm. That speculation led to the company reaching a new high of just below $65 a share. Due to the recent gain in stock price however, Thermo Fisher Scientific Inc has reportedly withdrawn their offer to buyout the company at current price levels. A potential deal with Thermo Fisher Scientific would compliment both companies' current portfolio of life sciences tools, although it is rumored that Thermo Fisher doubts their offer will be accepted by the Life Technologies' board at current price levels.
In more positive news yesterday, Life Technologies also released details of an expansion of their Ion Torrent systems. They announced about a dozen new products that the company expects to continue the push to become the market leader in bench top genome sequencers, already controlling about 60% of the market. There has been great demand for the company's sequencers, driving revenue growth in the fourth quarter.
Overall, the news is underwhelming and its disappointing to see that buyout talks have reportedly stalled between Life Technologies and its potential suitors. At its current price targets, the life sciences company is trading above average in both earnings and EV/EBITDA relative to its peers. We will be waiting to see how the stock performs today to decide whether to exclude it from the portfolio and will update if any decisions are made.
Anadarko Guidance
Today Anadarko released details of its 2013 capital program and guidance. 2013 is expected to be one of the best years in company history. Capital Expenditures are estimated to be within the range of $7.2-$7.6 billion and will focus on projects that are estimated to generate return rates between 30 and 100 percent. Sales volume is expected to increase 5 percent, with high margin oil sales justifying most of the increase. The increase in oil sales will be primarly driven by increased activity in the Wattenberg and Eagleford horizontal programs. Furthermore, Anadarko remains focused on creating value by advancing high margin international oil and deep water development mega projects in Mozambique, Ghana, and Algeria, as well as continuing a very active exploration program.
Anadarko closed at $80.37, down 4.47 percent primarily due to worries concerning the possibility of Quantitative Easing ending prematurely. Equities within the energy space suffered the most losses because they are primarily driven by prospects of future economic growth. An end to QE in addition to a possibility of the debt crisis going unsolved has sent investors fleeing.
Despite today's bear run I do not believe QE will end anytime soon because the Fed has not come close to reaching its goal of 6.5 percent unemployment. I do not believe the Fed will end QE before budget cuts are negotiated on the contrary, a new QE program might be necessary to absorb the impact they will have on the U.S. economy.
Anadarko closed at $80.37, down 4.47 percent primarily due to worries concerning the possibility of Quantitative Easing ending prematurely. Equities within the energy space suffered the most losses because they are primarily driven by prospects of future economic growth. An end to QE in addition to a possibility of the debt crisis going unsolved has sent investors fleeing.
Despite today's bear run I do not believe QE will end anytime soon because the Fed has not come close to reaching its goal of 6.5 percent unemployment. I do not believe the Fed will end QE before budget cuts are negotiated on the contrary, a new QE program might be necessary to absorb the impact they will have on the U.S. economy.
Sunday, February 17, 2013
VFC 4Q12 Earnings
V.F. Corporation released 4Q12 earnings pre-market on Friday, February 15 and the stock is up 3.3% since the release. VFC reported adjusted EPS of $3.07 for the quarter, up ~32% year-over-year and ahead of street expectations of $3.03. This was driven by strong top-line growth and improved margins. Sales missed estimates, however it grew 4% compared to 4Q11, to $3.003 billion. The sale of John Varvatos during the year had a 1% negative impact on revenues. Gross margin was up 220 basis points to 47.4% from 45.2% in 4Q11 while operating margin expanded 280bp to 15.1%.
The Outdoor and Sportswear segments saw year-over-year revenue gains of 6% and 15%, respectively. Jeanswear, Imagewear, International, and Direct-to-Consumer also saw gains during the quarter. Contemporary Brands' revenue was down 17% during the quarter due to the sale of John Varvatos, however, operating income surged 20% during the quarter.
The company expects 2013 revenues to grow 6% and margins to expand by ~100bp. The company also prides itself in its ability to generate cash and expects cash flow to reach a record $1.4 billion.
VFC was able to sustain top-line growth during a quarter when many competitors slumped. Their diverse portfolio of big-name brands helps to hedge against both fashion risk and weather fluctuations. The company is actively seeking new acquisition targets to strengthen the company and we remain very bullish on VFC in the long-term.
The Outdoor and Sportswear segments saw year-over-year revenue gains of 6% and 15%, respectively. Jeanswear, Imagewear, International, and Direct-to-Consumer also saw gains during the quarter. Contemporary Brands' revenue was down 17% during the quarter due to the sale of John Varvatos, however, operating income surged 20% during the quarter.
The company expects 2013 revenues to grow 6% and margins to expand by ~100bp. The company also prides itself in its ability to generate cash and expects cash flow to reach a record $1.4 billion.
VFC was able to sustain top-line growth during a quarter when many competitors slumped. Their diverse portfolio of big-name brands helps to hedge against both fashion risk and weather fluctuations. The company is actively seeking new acquisition targets to strengthen the company and we remain very bullish on VFC in the long-term.
Friday, February 15, 2013
ALXN reports Q4 and 2012 earnings
On February 14th, Alexion Pharmaceuticals reported Q4 and 2012 full year results. For Q4 2012 net product sales of soliris increased 41 percent to $320.5 million, compared to $227.6 million in Q4 2011. This increase represents steady additions of new patients with PHN globally and new patients with aHUS. Q4 2012 non-GAAP net income increased 52 percent to $122.3million, or $0.60 per share, compared to Q4 2011 non-GAAP net income of $80.5 million, or $0.41 per share. Overall ALXN had steady increases for Q4 2012. For the year 2012 net product sales increased 45 percent to $1.134 billion, compared to $783.4 million in 2011. 2012 non-GAAP net income increased 60 percent to $425.2 million, or $2.13 per share, compared to 2011 non-GAAP net income of $266.1 million, or $1.38 per share. As of December 31, 2012, the Company had $989.5 million in cash and cash equivalents compared to $540.9 million at December 31, 2011. Compared to 2011, Alexion has improved overall in 2012. In 2013, worldwide net product sales are expected to be within a range of $1.490 to $1.505 billion. On a non-GAAP basis, R&D expenses are expected to be in the range of $285 to $295 million, and SG&A expenses in the range of $425 to $435million. Cost of sales is expected to be approximately 10 percent of net product sales. The non-GAAP effective tax rate ,reported on a cash tax liability basis, is expected to be in the range of 7 to 9 percent. Based on a forecast of approximately 205 million diluted shares outstanding, Alexion is providing guidance of $2.82 to $2.92 for non-GAAP earnings per share for the year. Alexion plans to continue to grow and expand their market in 2013 which will lead to further increases and improvements throughout the year.
-->
DaVita healthcare Partners released their 4Q earning that ended December 31, 2012 and reported on February 14, 2013. In this quarter DaVita completed the acquisition of HealthCare partners. They reported earnings of $173.3 million, or $1.68 per share—excluding the transaction expenses associated with the acquisition costs of HealthCare partners—compared to $1.57 in the year earlier quarter. This beat the streets expectation by $.25. Revenue rose 33.05 percent to 2.48 billion rom the year earlier quarter. Net income was 155.8 million, or $1.51 per share. Operating cash flow was 1,101 million and free cash flow was 715 million.
Management noted in their earning conference call that as part of the fiscal cliff negotiations congress mandated a rebasement of part of the bundle (payments by Medicare and Medicaid) for 2014. Which could lead to headwinds for kidney care providers, such as DaVita, in 2014. Currently, the kidney care providers are losing money on Medicare and many of the dialysis centers in America “ are in a fragile financial state”. However, management is confident that they will be able to reduce total cost while at the same time improving quality of care. Some of those costs will be actualized by the further vertical integration of Healthcare partners and the resulting greater efficiency. Management also touched on the increasing risk of the often-discussed government investigations and private lawsuits.
In the near-term outlook, management maintained 2013 OI guidance of $1.75 billion to $1.9 billion, and this includes, on the kidney care side, $1.35 billion to $1.45 billion; and on the HeathCare Partners side, $400 million to $450 million.
DaVita has continued to post solid financial gains despite the uncertainty that exists in the healthcare sector. The company proven the ability to diversify and integrate vertically, with its acquisition of HealthCare Partners. DaVita's emphasis on quality of care and their vast network of dialysis centers has given the company a great competitive advantage in the Kidney care provider sector.
It is noteworthy to mention that Berkshire Hathaway bought an additional $3,728,844 worth of DaVita shares bringing their ownership to nearly 15 percent of the company.
Thursday, February 14, 2013
DE Sell Thesis
Deere and Company reported 1st quarter earnings
today of 1.65 beating analyst consensus by 18 percent on revenues of 7.4
billion which also beat expectations by about 17 percent. Although this quarter
was very good for Deere and Company, the stock has fallen approximately 3
percent thus far today. Deere agriculture and turf was the primary driver of
growth with sales of 16 percent over the first quarter of 2012. On the other
side, the biggest laggard was Deere construction and forestry, which saw sales
drop 7 percent over first quarter 2012. Moving forward, I believe that we
should exit our position in Deere and Company. Although agriculture equipment
sales should continue to grow over 10 percent in Latin America, Europe sales
for 2013 were revised down from flat to down 5 percent to down 5 percent as a
result of a weak economic environment combined with a poor crop harvest from
the United Kingdom. Additionally new import duties will hurt demand in Russia
and Belarus in 2013 and high grain prices for livestock farmers will cause
agriculture equipment sales in the United States and Canada to be flat over
2012. Also, construction and forestry equipment sales, which struggled in
quarter 1, are expected to continue throughout 2013 primarily as a result of
forestry equipment sales in North America seeing limited growth. Production,
SG&A costs, and warranty costs rose in quarter 1 and that is also going to
continue through 2013. Production costs rose from the additional costs from
manufacturing more energy efficient engines. This could potentially hurt
margins in 2013. Although long, term macro factors are positive, in the nearer
term, the company has said that economic, fiscal, and trade factors could have
a negative impact on the business. All these factors together and I believe
that now is the time to sell Deere and Company.
-Andrew Henderson, Junior Industrial Analyst
Wednesday, February 13, 2013
BlackRock Names New CFO
BlackRock announced Wednesday February 13, 2013 that Gary Shedlin has been selected to become the next CFO. Ann Marie Petach, the company’s long existing CFO will be retiring from her position.
Gary Shedlin is known for being the dealmaker leading BlackRock’s massive acquisition of Barclay’s iShares Unit in 2009. Gary Shedlin is moving to BlackRock from Morgan Stanley.
In response to speculation that BlackRock is beginning positioning it’s self for new acquisitions Robert Kapito, the President, spoke up against those claims. Mr. Kapito noted that the firm would continue to focus on small acquisitions to round off product lines. BLK shares up +1.44% intraday.
-Source: Reuters.
Subscribe to:
Posts (Atom)